NASDAQ
28.10.25 | 20:59
13,540 US-Dollar
-1,96 % -0,270
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| PHATHOM PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| Sa | Phathom: Neue Studiendaten belegen Wirksamkeit von Vonoprazan bei nächtlichen Reflux-Symptomen | 3 | Investing.com Deutsch | ||
| Sa | Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease | 2 | GlobeNewswire (USA) | ||
| Do | Phathom Pharmaceuticals to Highlight VOQUEZNA (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting | 4 | GlobeNewswire (USA) | ||
| 20.10. | Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025 | 4 | GlobeNewswire (USA) | ||
| 15.10. | Phathom stock remains Overweight at Cantor Fitzgerald on sales strategy shift | 1 | Investing.com | ||
| 15.10. | Strategiewechsel im Vertrieb: Cantor Fitzgerald stuft Phathom-Aktie weiter mit "Overweight" ein | 4 | Investing.com Deutsch | ||
| 09.10. | Cantor Fitzgerald reiterates Phathom stock as top pick with $29 price target | 2 | Investing.com | ||
| 09.10. | Cantor Fitzgerald bestätigt Phathom als Top-Pick mit Kursziel von 29 US-Dollar | 3 | Investing.com Deutsch | ||
| 06.10. | Phathom Pharmaceuticals Appoints Sanjeev Narula As Chief Financial And Business Officer | 2 | RTTNews | ||
| 06.10. | Phathom Pharmaceuticals appoints Sanjeev Narula as chief financial officer | 1 | Investing.com | ||
| 06.10. | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.08. | Phathom Pharmaceuticals clarifies no reduction in Frazier ownership | 2 | Investing.com | ||
| 20.08. | Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder's Ownership Following Administrative Change to 13D Filing | 1 | GlobeNewswire (USA) | ||
| 08.08. | Phathom projects $165M-$175M 2025 revenue as GI sales focus accelerates VOQUEZNA growth | 2 | Seeking Alpha | ||
| 07.08. | Phathom Pharmaceuticals Q2 2025 slides: VOQUEZNA growth drives revenue beat | 1 | Investing.com | ||
| 07.08. | Phathom Pharmaceuticals GAAP EPS of -$1.05 misses by $0.01, revenue of $39.5M beats by $3.92M | 2 | Seeking Alpha | ||
| 07.08. | Phathom Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 07.08. | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.07. | Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025 | 2 | GlobeNewswire (USA) | ||
| 23.06. | Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 367 | GlobeNewswire (Europe) | FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INOVIO PHARMACEUTICALS | 2,180 | 0,00 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Inducement Grant Under Inducement Plan | PLYMOUTH MEETING, Pa., Oct. 2, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| TREVENA | 2,280 | -40,00 % | Hollywood Changemaker Oliver Trevena Joins Little Kitchen Academy as Investor | LOS ANGELES, CA / ACCESS Newswire / August 21, 2025 / Little Kitchen Academy (LKA), the premier Montessori-inspired cooking academy for children and teens ages 3-18, is proud to announce that Oliver... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 20,940 | +3,71 % | Sarepta-Aktie: Zurück zu altem Glanz? | Die Aktie von Sarepta Therapeutics steht wieder im Fokus der Biotech-Anleger. Nach einem starken Umsatzwachstum und hohen Erwartungen an neue Gentherapien fragen sich viele, ob das Papier seinen nächsten... ► Artikel lesen | |
| IBIO | 1,190 | +9,17 % | Why Did iBio Shares Surge Over 11% In Pre-Market Trading? | ||
| MYRIAD GENETICS | 7,200 | +3,60 % | Myriad Genetics, Inc.: Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025 | ||
| T2 BIOSYSTEMS | 0,250 | 0,00 % | NSE/A - T2 Biosystems, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| BIOXCEL THERAPEUTICS | 1,842 | -6,12 % | BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements | NEW HAVEN, Conn., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,025 | -44,44 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 21.10.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 21.10.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 21.10.2025.ISIN NameCA80013R2063 SANDSTORM... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 3,447 | +2,53 % | FDA Acceptance Of Rocket Pharmaceuticals' Lead Gene Therapy Application Reestablishes Momentum For Stock | ||
| MACROGENICS | 1,625 | -0,67 % | MacroGenics, Inc.: MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities | Newly-appointed President and CEO, Eric Risser, outlines strategic priorities for 2025 and 2026 Received $70 million upfront cash payment from Sagard Healthcare Partners under a royalty purchase agreement... ► Artikel lesen | |
| SPERO THERAPEUTICS | 1,890 | -3,67 % | GSK unveils positive pivotal data for Spero's once-rejected oral antibiotic | ||
| SCILEX | 18,020 | -4,76 % | Scilex Holding Company Announces the Completion of the First Tranche of the Oramed Pharmaceuticals, Inc. Warrant Repurchase | PALO ALTO, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and... ► Artikel lesen | |
| X4 PHARMACEUTICALS | 2,450 | -100,00 % | X4 Pharmaceuticals raises $155.3 million in public offering | ||
| GENERATION BIO | 5,820 | -2,84 % | Generation Bio Co.: Generation Bio Announces CEO Transition | • Geoff McDonough, MD to step down as CEO & President and become Chair of the Company's Board of Directors • Current Chief Legal Officer Yalonda Howze, JD named Interim CEO & President CAMBRIDGE,... ► Artikel lesen | |
| INVIVYD | 2,105 | -2,55 % | Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID |
PHATHOM PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,270 (-1,96 %) liegt der Kurs bei 13,540 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHATHOM PHARMACEUTICALS INC finden Sie auf Wallstreet Online.